# Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer

Source: https://onco.cc/trials/nct06667960/  
OnCo record `nct06667960` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of JK06 in advanced solid tumours, run by Salubris Biotherapeutics Inc, now recruiting.

## Summary

Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer is a phase 1/2 interventional study registered as NCT06667960 by Salubris Biotherapeutics Inc, with 255 participants planned, started 2024-10-23 and due to reach its primary completion in 2028-04-01. Interventions recorded: JK06.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06667960
- Phase: 1/2
- Setting: A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Sponsor: Salubris Biotherapeutics Inc
- Enrolled: 255

## Sources

- ClinicalTrials.gov NCT06667960: https://clinicaltrials.gov/study/NCT06667960

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06667960.json